{"denoms":[{"counts":[{"groupId":"BG000","value":"109"}],"units":"Participants"}],"groups":[{"description":"Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophosphamide with MESNA, Doxorubicin hydrochloride, Etoposide, Ifosfamide with MESNA. Weeks 35-54: vincristine sulfate, Dactinomycin, irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.","id":"BG000","title":"High_Risk_Rhabdomyosarcoma"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"96"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"6.55","value":"11.85"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"49"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"60"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"86"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"76"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"92"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Australia"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}